A landmark multi-hundred million dollar collaboration between Takeda and BridGene Biosciences redefines biotech funding trends this week, joined …
A landmark multi-hundred million dollar collaboration between Takeda and BridGene Biosciences redefines biotech funding trends this week, joined …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
As traditional VC investment remains selective, firms like Abingworth and Vie Ventures are pioneering fresh approaches—launching billion-dollar trials …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
With a blockbuster IPO on the horizon, Australian biotech innovation is drawing global eyes and fresh capital to …
New partnerships and funding rounds are powering the rapid growth of RNA therapeutics.
New device approval and robust oncology funding highlight ongoing biopharma momentum in cancer therapies.
While VC investment cools, innovative startups find new ways to fuel biotech innovation and clinical progress.
Already a subscriber? Log in